Navigation Links
Savient Pharmaceuticals to Present at the Cowen and Company 32nd Annual Health Care Conference
Date:2/23/2012

EAST BRUNSWICK, N.J., Feb. 23, 2012 /PRNewswire/ -- Savient Pharmaceuticals, Inc. (NASDAQ: SVNT) today announced that Kenneth Zuerblis, Executive Vice President and Chief Financial Officer of Savient will present at the Cowen and Company 32nd Annual Health Care Conference on Tuesday, March 6, 2012 at 10:40 AM Eastern Time.  The conference will be held at the Boston Marriott Copley Place in Boston, MA.

A live webcast of the presentation can be accessed through the investor relations section of the Company's website at www.savient.com.  Following the live presentation, a replay of the webcast will be available on the Company's website for 30 days.

ABOUT SAVIENT PHARMACEUTICALS, INC.Savient Pharmaceuticals, Inc. is a specialty biopharmaceutical company focused on developing and commercializing KRYSTEXXA® (pegloticase) for the treatment of chronic gout in adult patients refractory to conventional therapy. Savient has exclusively licensed worldwide rights to the technology related to KRYSTEXXA and its uses from Duke University ("Duke") and Mountain View Pharmaceuticals, Inc. ("MVP").  Duke developed the recombinant uricase enzyme and MVP developed the PEGylation technology used in the manufacture of KRYSTEXXA. MVP and Duke have been granted U.S. and foreign patents disclosing and claiming the licensed technology and, in addition, Savient owns or co-owns U.S. and foreign patents and patent applications, which collectively form a broad portfolio of patents covering the composition, manufacture and methods of use and administration of KRYSTEXXA.  Savient also manufactures and supplies Oxandrin® (oxandrolone tablets, USP) CIII in the U.S. For more information, please visit the Company's website at www.savient.com.Contact:  Mary Coleman Carney Noensie Savient Pharmaceuticals, Inc. Burns McClellan information@savient.com  cnoensie@burnsmc.com (732) 418-9300  (212) 213-0006SVNT - G


'/>"/>

SOURCE Savient Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Savient Pharmaceuticals to Present at the Citi 2012 Global Health Care Conference
2. Savient Pharmaceuticals Appoints David Y. Norton Interim Chief Executive Officer
3. Savient Pharmaceuticals Appoints Experienced Pharmaceutical Executive, David Veitch as President of Savient Europe
4. Savient Pharmaceuticals Announces Permanent J-Code Assigned for KRYSTEXXA®
5. Savient Pharmaceuticals to Present at the Noble Financial Capital Markets Eighth Annual Equity Conference
6. Savient Pharmaceuticals Announces New Data Surrounding KRYSTEXXA® and the Impact of Refractory Chronic Gout at the American College of Rheumatology Meeting
7. Savient Pharmaceuticals Reports Third Quarter 2011 Financial Results
8. Savient Pharmaceuticals to Hold Third Quarter 2011 Financial Results Conference Call on Thursday, November 3, 2011
9. Savient Pharmaceuticals to Present at the Sixth Annual JMP Securities Healthcare Conference
10. Savient Pharmaceuticals Names Kenneth J. Zuerblis Chief Financial Officer
11. Savient Pharmaceuticals Announces Publication of Pivotal Phase III KRYSTEXXA® Data in JAMA Demonstrating Significant Benefits in Refractory Chronic Gout Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/4/2017)... -- Agragen, LLC, a Cincinnati -based ... and aquacultural feed sectors, announces a significant step ... AGR131.  This drug is designed to trap and ... patients suffering from inflammatory conditions such as rheumatoid ... Biological pharmaceuticals currently used ...
(Date:8/2/2017)... MEMPHIS, Tenn. and BENTON, Ky. , Aug. 2, 2017 /PRNewswire/ ... new member to its environmental services (ES) team to proactively reduce the risk of hospital-acquired ... is a UV disinfection robot that uses UVC light energy to kill deadly pathogens such ... ... Tru-D ...
(Date:8/1/2017)... , Aug. 1, 2017   CerSci Therapeutics , ... Dallas, Texas , has received notice from the ... Institutes of Health (NIH) that it has been awarded ... totaling over $650,000 in 2017 with an additional $1,000,000 ... Investigational New Drug application of their lead non-opioid drug ...
Breaking Medicine Technology:
(Date:8/21/2017)... , ... August 21, 2017 , ... ... addition of two plastic surgery fellows for academic year 2017-2018, Christina M. Busuito, ... who have successfully completed residency in Plastic and Reconstructive Surgery. The candidate ...
(Date:8/21/2017)... California (PRWEB) , ... August 21, 2017 , ... Five ... money and awareness for Alzheimer’s Family Center. , Guests will be able to ... Newport Beach Plaza, Braised Lamb Shank with Fennel Dill Salad, Feta Cheese Sauce & ...
(Date:8/21/2017)... (PRWEB) , ... August 21, 2017 , ... The experts ... exactly are we supposed to get things done in a healthy way these days? ... they’re launching a crowdfunding campaign on August 28 to introduce Deskcise Pro™– the world’s ...
(Date:8/21/2017)... ... August 21, 2017 , ... San Diego physician and surgeon Dr. James ... has announced his candidacy for the 52nd Congressional District currently held by Representative Scott ... Coming to this country at age eleven after suffering homelessness and hardship in a ...
(Date:8/20/2017)... ANGELES, Calif. (PRWEB) , ... August 20, 2017 , ... A total solar eclipse ... darken for a few minutes as the moon moves between the sun and Earth. This ... , These four tips can help keep you safe on the road during the ...
Breaking Medicine News(10 mins):